A Phase III Randomized, Double-Blind Study Of SU011248 (Sunitinib, SUTENT), A Oral Novel Multitargeted Tyrosine Kinase Inhibitor, Given Daily As A Continuous Dose Versus Placebo In Patients With Advanced/Metastatic Neuroendocrine Tumours Of The Digestive Tract.

Trial Profile

A Phase III Randomized, Double-Blind Study Of SU011248 (Sunitinib, SUTENT), A Oral Novel Multitargeted Tyrosine Kinase Inhibitor, Given Daily As A Continuous Dose Versus Placebo In Patients With Advanced/Metastatic Neuroendocrine Tumours Of The Digestive Tract.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 12 Nov 2017

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Neuroendocrine carcinoma; Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 12 Nov 2017 Results of an investigator-initiated post hoc analysis (n=237) assessing an alternative cut-off for definition of partial response able to predict clinical benefit from treatment with sunitinib in patients diagnosed with pancreatic neuroendocrine tumours using individual data of patients from the phase II [NCT00056693] and phase III [NCT00428597] trials, published in the British Journal of Cancer.
    • 12 Oct 2017 Results of pooled data assessing effectiveness of sunitinib and everolimus in patients with pancreatic neuroendocrine tumours from two trial (RADIANT-3 and A6181111 ), were presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
    • 06 Dec 2016 Results (n=144) assessing patient-reported outcomes and quality of life, published in the Targeted Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top